HC Wainwright Weighs in on Edap Tms FY2030 Earnings

Key Points

• HC Wainwright forecasts Edap Tms will earn $0.12 per share in FY2030 and assigns a Buy rating with a $10 price target, well above the consensus full‑year estimate of ($0.60) and the street average price target of $6.00.
• Edap’s latest quarter showed an EPS of ($0.25), missing the ($0.16) consensus while revenue of $22.22 million beat estimates, leaving the company unprofitable with negative margins and a market cap around $126 million (share price roughly $3.36).

Edap Tms S.A. (NASDAQ:EDAP - Free Report) - Equities researchers at HC Wainwright issued their FY2030 earnings per share estimates for Edap Tms in a research report issued on Thursday, April 9th. HC Wainwright analyst S. Ramakanth anticipates that the medical equipment provider will post earnings of $0.12 per share for the year. HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Edap Tms' current full-year earnings is ($0.60) per share.

EDAP has been the subject of a number of other reports. Weiss Ratings restated a "sell (d-)" rating on shares of Edap Tms in a report on Monday, December 29th. Wall Street Zen cut shares of Edap Tms from a "hold" rating to a "sell" rating in a report on Saturday, March 28th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $6.00.

Edap Tms Stock Down 0.3%

Shares of NASDAQ EDAP opened at $3.36 on Friday. The company has a quick ratio of 1.19, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. The firm has a market cap of $125.63 million, a PE ratio of -4.36 and a beta of -0.09. The company's fifty day simple moving average is $4.12 and its 200 day simple moving average is $3.22. Edap Tms has a 12-month low of $1.21 and a 12-month high of $5.05.

Edap Tms (NASDAQ:EDAP - Get Free Report) last issued its earnings results on Wednesday, March 25th. The medical equipment provider reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.09). The business had revenue of $22.22 million during the quarter, compared to the consensus estimate of $21.28 million. Edap Tms had a negative return on equity of 100.07% and a negative net margin of 41.24%.

Institutional Investors Weigh In On Edap Tms

Large investors have recently bought and sold shares of the stock. Financial Planning Navigators CORP acquired a new stake in Edap Tms in the fourth quarter worth $33,000. Kovack Advisors Inc. bought a new position in shares of Edap Tms in the fourth quarter valued at $53,000. Leonteq Securities AG bought a new position in shares of Edap Tms in the fourth quarter valued at $313,000. Flax Pond Capital LLC bought a new position in shares of Edap Tms in the fourth quarter valued at $2,623,000. Finally, Rock Springs Capital Management LP lifted its stake in shares of Edap Tms by 1.3% in the fourth quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the medical equipment provider's stock valued at $4,233,000 after buying an additional 16,500 shares in the last quarter. 62.74% of the stock is currently owned by institutional investors and hedge funds.

About Edap Tms

Edap Tms SA NASDAQ: EDAP is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm's core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms's Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.